The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
about
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasTime course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C.Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancerMechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.The Servier oncology pipeline in 2017.Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells
P2860
Q33728214-EC7338E1-4B15-4C25-A537-989BABE37737Q33873796-7525B31D-464B-4687-ADC9-4E2BA6A450F2Q34172879-3B854B8F-525A-4C89-B37D-07A8514490AFQ36559677-FE2BF422-D748-4A7D-B54C-DF37AC5FA4DDQ37178611-AAAE7277-2A13-4430-B370-0DAB70147755Q37357478-163E70F6-F7EC-4C6C-9606-54FB41471B88Q37633429-9C729900-3566-4A2B-9251-DB49793D436BQ38190105-5342212F-B4C3-4BA4-AF40-8F3EBEA986A6Q38692664-7D67CB65-16E1-4805-B8B6-3908D04B7A37Q38819940-2E893C57-3154-4737-ABBF-D00EB8C6BB23Q38852772-F8351A27-4992-4CF5-81F6-B351E207D734Q38913918-8E3B5613-4CF7-4FA3-B1EA-DA913101DECBQ38984987-DC73B8E5-72E1-44DD-9E92-B33D35825CBBQ40628996-B28F5FE7-A80B-4924-B0A2-D72CA5BDB133Q43412243-01A5DBD5-4ABF-4928-92FD-C32649E7745CQ44950915-0A8B96AD-4544-46A9-A229-ECCB2E8B4A00Q46431115-E1168BB8-A897-4412-8053-BBA1FE349425Q55222160-F90D7ED7-3EBF-42D7-8011-3A54F6AD34D3Q55504476-40E742E0-800E-49B4-B686-D5B51AA9A710Q58798568-40AA9243-9B5C-44AF-B969-8E73ABAF88FF
P2860
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The novel anthracenedione, pix ...... doxorubicin-treated patients.
@en
The novel anthracenedione, pix ...... doxorubicin-treated patients.
@nl
type
label
The novel anthracenedione, pix ...... doxorubicin-treated patients.
@en
The novel anthracenedione, pix ...... doxorubicin-treated patients.
@nl
prefLabel
The novel anthracenedione, pix ...... doxorubicin-treated patients.
@en
The novel anthracenedione, pix ...... doxorubicin-treated patients.
@nl
P50
P356
P1476
The novel anthracenedione, pix ...... n doxorubicin-treated patients
@en
P2093
Odalys Gonzalez Paz
P304
P356
10.1124/JPET.112.200568
P407
P577
2012-11-28T00:00:00Z